Mean Platelet Volume Is a Poor Prognostic Factor in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

被引:0
|
作者
Senturk, Mustafa [1 ]
Ince, Volkan [1 ]
Ureyen, Orhan [2 ]
Eyvaz, Kemal [3 ]
Isik, Burak [1 ]
Carr, Brian, I [1 ]
Yilmaz, Sezai [1 ]
机构
[1] Inonu Univ, Liver Transplant Inst, Dept Surg, Malatya, Turkiye
[2] Hlth Sci Univ, Izmir Bozyaka Training & Res Hosp, Dept Gen Surg, Izmir, Turkiye
[3] Univ Hlth Sci, Antalya Educ & Res Hosp, Dept Gen Surg, Antalya, Turkiye
来源
TURKISH JOURNAL OF GASTROENTEROLOGY | 2025年 / 36卷 / 03期
关键词
MPV; hepatocellular cancer; transplantation;
D O I
10.5152/tjg.2025.24540
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Mean platelet volume (MPV) reflects platelet activation. Platelets have an important role in tumor progression and metastasis. In this study, we wanted to investigate the effect of MPV on survival in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Materials and Methods: All data of 376 patients who underwent LT and pathologically diagnosed with HCC were analyzed. Bydetermin- ing the cut-off of MPV (10.2 fL), 2 groups with high and low MPV were formed. The groups were compared within themselves. Factors affecting survival were determined by univariate and multivariate analysis. Results: When the groups were compared, patients with low MPV had significantly higher platelet counts, larger tumor sizes, lower BMI, and higher recurrence rates. In multivariate analysis, GGT >104, AFP >200 mu g/L, largest tumor diameter >5 cm, and lower MPV were found to be independent risk factors that affected the prognosis. Tumor-free survival was significantly worse in the lower MPV group (P = .002). Conclusion: Pre-transplant low MPV maybe useful in predicting poor prognosis and a high rate of tumor recurrence in patients with HCC after liver transplantation.
引用
收藏
页数:71
相关论文
共 50 条
  • [21] Sarcopenia Is Poor Prognostic Factor in Patients With Hepatocellular Carcinoma After Hepatectomy
    Shirabe, Ken
    Maehara, Yoshihiko
    GASTROENTEROLOGY, 2013, 144 (05) : S1044 - S1044
  • [22] Prognostic genomic alterations in patients undergoing liver resection for hepatocellular carcinoma
    Nordkild, Sb
    Ahlborn, Lb
    Yde, Cw
    Kugler, Jm
    Klubien, J.
    Akdag, D.
    Willemoe, Gl
    Nielsen, Sd
    Pommergaard, Hans-Christian
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [23] Prognostic value of mean platelet volume in patients undergoing elective percutaneous coronary intervention
    Seyyed-Mohammadzad, Mir Hossein
    Eskandari, Ramin
    Rezaei, Yousef
    Khademvatani, Kamal
    Mehrpooya, Maryam
    Rostamzadeh, Alireza
    Zahedi, Afshin
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2015, 15 (01): : 25 - 30
  • [24] Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
    Lee, Hae Lim
    Lee, Sung Won
    Jang, Jeong Won
    Bae, Si Hyun
    Choi, Jong Young
    Yoon, Seung Kew
    Choi, Ho Joong
    Na, Gun Hyung
    You, Young Kyoung
    Park, Il Young
    Kim, Dong Goo
    LIVER TRANSPLANTATION, 2022, 28 (03) : 397 - 406
  • [25] mTOR inhibition for patients with hepatocellular carcinoma undergoing liver transplantation: is there a rationale?
    Sieghart, Wolfgang
    Fuereder, Thorsten
    Schmid, Katharina
    Cejka, Daniel
    Wrba, Fritz
    Wang, Xiaowei
    Gruber, Diego
    Rasoul-Rockenschaub, Susanne
    Peck-Radosavljevic, Markus
    Wacheck, Volker
    CANCER RESEARCH, 2006, 66 (08)
  • [26] Outcome of cirrhotic patients with incidental hepatocellular carcinoma undergoing liver transplantation
    Charco, R
    Hidalgo, E
    Lázaro, JL
    Vargas, V
    Castells, L
    Murio, E
    Bilbao, I
    Margarit, C
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (01) : 299 - +
  • [27] Sarcopenia and AFP Level in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation
    Safer, Vildan Binay
    Eyigor, Sibel
    JOURNAL OF SURGICAL RESEARCH, 2019, 243 : 574 - 575
  • [28] Pulmonary nodules at risk in patients undergoing liver transplantation for hepatocellular carcinoma
    Sotiropoulos, Georgios C.
    Kuehl, Hilmar
    Sgourakis, George
    Molmenti, Ernesto P.
    Beckebaum, Susanne
    Cicinnati, Vito R.
    Baba, Hideo A.
    Schmitz, Klaus J.
    Broelsch, Christoph E.
    Lang, Hauke
    TRANSPLANT INTERNATIONAL, 2008, 21 (09) : 850 - 856
  • [29] Hepatocellular carcinoma in patients undergoing living-donor liver transplantation
    Maetani, Yoji S.
    Ueda, Mikiko
    Haga, Hironori
    Isoda, Hiroyoshi
    Takada, Yasutsugu
    Arizono, Shigeki
    Hirokawa, Yuusuke
    Shimada, Kootaro
    Shibata, Toshiya
    Kaori, Togashi
    INTERVIROLOGY, 2008, 51 : 46 - 51
  • [30] mTOR inhibition for patients with hepatocellular carcinoma undergoing liver transplantation: Is there a rationale?
    Sieghart, W.
    Fuereder, T.
    Schmid, K.
    Cejka, D.
    Wrba, F.
    Wang, X.
    Gruber, D.
    Rasoul-Rockenschaub, S.
    Peck-Radosavljevic, M.
    Wacheck, V.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S109 - S109